Mary Caffrey

Reports say Azar is asserting control over FDA as vaccine trials near completion, while Hahn is blocked from testifying on COVID-19.

The 2020 meeting, presented in a virtual format from its original host city of Amsterdam, The Netherlands, had lots of important science and a record number of viewers.

A study from the European Society of Cardiology answers a question about COVID-19: should patients keep taking well-known heart medications?

Celiac disease was linked with a greater likelihood to be diagnosed with a mood disorder, ADHD, or an eating disorder.

Adaptive Biotechnologies’ clonoSEQ gets third approval; FDA also acts on first at-home treatment for spinal muscular atrophy.

The American College of Cardiology issues its second set of recommendations for its members on prescribing two groups of drugs first developed for type 2 diabetes.

In a busy week, FDA approved ground-breaking therapies in hematologic cancers and issued Orphan Drug designations in areas of significant unmet need.

Managed Healthcare Executive® (MHE) interviewed Jeff Hawkins, president and CEO of Truvian Sciences, about how Truvian received an Emergency Use Authorization (EUA) from FDA for Easy Check COVID-19 IgM/IgG antibody test.

Dr. Deepak Bhatt presents results that show Vascepa cuts the risk for surgeries to restore blood flow to the heart by a third.

Dr. David Ho, who developed the HIV cocktail, has isolated antibodies he says could be used to create treatments for COVID-19.

When Medicaid pays for food, it helps prevent chronic disease.

Guidelines to prevent retinopathy caused by a drug to treat autoimmune disease must be developed jointly by ophthalmologists and prescribing physicians, journal authors say.

Heart disease drugs were in the news this week.

More research is needed on how MS affects women throughout the life span.

Patients with diabetic macular edema whose vision remains impaired even with the best available treatments may soon have a combination therapy.

FDA outlines what it will take to get a COVID-19 vaccine approved, while NIH offers its research strategy.

FDA approves Merck's Keytruda for certain patients with metastatic colorectal cancer a month after study results were presented at ASCO.

Results from REDUCE-IT trial presented at the ADA meeting show that the fish-oil pill is associated with cardiovascular disease protection among patients with diabetes.

Former CareMore Health CEO Sachin Jain, MD, MBA, perhaps best known for his effort to treat loneliness among seniors as a health issue, has been named CEO of the SCAN Group and the SCAN Health Plan, a not-for-profit that focuses on this growing population.

Jeffrey Skolnik, MD, vice president, clinical development of Inovio Pharmaceuticals Inc Discusses Glioblastoma Treatment in ASCO interview.

Adrian Kilcoyne MD MBA MPH, vice president, US Medical Affairs and HEOR, oncology, AstraZeneca, discusses a paradigm shift in lung cancer treatment due to the overwhelming efficacy of the EGFR-TKI treatment.

Tagrisso, the targeted therapy made by AstraZeneca, could become the treatment of choice for the majority of lung cancer patients with mutations in a certain gene who are treated after surgery, based on findings presented this past weekend at the American Society of Clinical Oncology annual meeting.

Keytruda, the immunotherapy with more than 20 indications in both blood and solid tumor cancers, doubled rates of progression-free survival for certain patients with metastatic colorectal cancer, according to results presented Sunday at the American Society of Clinical Oncology annual meeting.

A fresh look at MURANO data, released this week at the American Society of Clinical Oncology 2020 Annual meeting, shows the poor outcomes that result when patients halt treatment for good, and highlight the need to manage doses carefully to avoid toxicity.

The 2020 annual meeting of the American Society of Clinical Oncology that launches today will feature the first results from CITYSCAPE, a trial involving a novel immunotherapy approach in non-small cell lung cancer (NSCLC). This phase 2 trial is the first to combine the immunotherapy tiragolumab with atelzolizumab (Tecentriq), the monoclonal antibody that targets the programmed cell death ligand-1 (PD-L1).

President Donald Trump issued broad guidelines for a re-opening of the US economy this week, outlining the COVID-19 regulations that should be in place while leaving final decisions to the nation’s governors.

This week’s favorites ran the gamut from tech to COVID-19.